SOL-GEL TECHN. IS-10 - Asset Resilience Ratio
SOL-GEL TECHN. IS-10 (4SG) has an Asset Resilience Ratio of 43.34% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4SG FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how SOL-GEL TECHN. IS-10's Asset Resilience Ratio has changed over time. See 4SG net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down SOL-GEL TECHN. IS-10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SOL-GEL TECHN. IS-10 (4SG) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €12.97 Million | 43.34% |
| Total Liquid Assets | €12.97 Million | 43.34% |
Asset Resilience Insights
- Very High Liquidity: SOL-GEL TECHN. IS-10 maintains exceptional liquid asset reserves at 43.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SOL-GEL TECHN. IS-10 Industry Peers by Asset Resilience Ratio
Compare SOL-GEL TECHN. IS-10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for SOL-GEL TECHN. IS-10 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for SOL-GEL TECHN. IS-10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.34% | €12.97 Million ≈ $15.16 Million |
€29.92 Million ≈ $34.98 Million |
+30.96pp |
| 2024-12-31 | 12.38% | €4.44 Million ≈ $5.19 Million |
€35.85 Million ≈ $41.91 Million |
-54.93pp |
| 2023-12-31 | 67.31% | €30.48 Million ≈ $35.64 Million |
€45.29 Million ≈ $52.95 Million |
+21.89pp |
| 2022-12-31 | 45.42% | €21.18 Million ≈ $24.76 Million |
€46.63 Million ≈ $54.51 Million |
+11.95pp |
| 2021-12-31 | 33.47% | €23.16 Million ≈ $27.07 Million |
€69.19 Million ≈ $80.89 Million |
-- |
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more